id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-326468-xcy7v1tf	Mehta, R. M.	A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis	2020-11-10		.txt	text/plain	3696	223	54	title: A shorter symptom-onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis The current study aimed to evaluate the impact of timing of remdesivir initiation (symptom-onset to remdesivir treatment [SORT] interval) on in-hospital all-cause mortality in patients with moderate-to-severe COVID-19. This study aimed to evaluate the impact of symptom-onset to remdesivir treatment (SORT) interval on clinical outcomes in the subsets of moderate-to-severe COVID-19. This study primarily evaluated the association between SORT interval and clinical outcomes in moderate-to-severe COVID-19 and other relevant clinical endpoints, such as overall all-cause mortality, LOHS, and safety in remdesivir-treated patients. The importance of early remdesivir initiation (SORT interval ≤9 days) in our study with a clear outcome benefit indicates an impact of the medication even with steroids and ancillary therapies in moderate-to-severe COVID-19.	./cache/cord-326468-xcy7v1tf.txt	./txt/cord-326468-xcy7v1tf.txt